Discriminative-stimulus effects of cannabidiol oil in Sprague-Dawley rats.
Journal
Behavioural pharmacology
ISSN: 1473-5849
Titre abrégé: Behav Pharmacol
Pays: England
ID NLM: 9013016
Informations de publication
Date de publication:
13 Dec 2023
13 Dec 2023
Historique:
medline:
12
12
2023
pubmed:
12
12
2023
entrez:
12
12
2023
Statut:
aheadofprint
Résumé
Cannabidiol (CBD) is one of the major centrally active phytocannabinoid components of cannabis, and has been approved by the FDA only for the treatment of seizures associated with three rare disorders. It has also been touted as a potential treatment for anxiety in place of more traditional treatments like benzodiazepines. Although there is some evidence of anxiolytic effects of CBD, its suitability as a substitute for benzodiazepines is unknown. This experiment was designed to assess the extent to which CBD shares interoceptive discriminative-stimulus properties with the anxiolytic drug chlordiazepoxide (CDP), a benzodiazepine. In the present experiment, a range of doses (0-1569 mg/kg) of over-the-counter CBD oil was administered (i.g.) in male Sprague-Dawley rats trained to discriminate 5.6 mg/kg CDP from saline. Due to the long time-course effects of CBD, generalization tests were conducted at 90 and 120 min post-CBD administration. The two highest doses of CBD tested (1064 and 1569 mg/kg) were found to partially substitute for 5.6 mg/kg CDP, with mean percent responding on the CDP-associated lever reaching above 20% at time 2 (120 min post-CBD administration), suggesting that high doses of the over-the-counter CBD oils used in this experiment share interoceptive discriminative-stimulus properties to some degree with CDP. These results are novel in comparison to existing research into stimulus effects of CBD, in which substitution for benzodiazepines has not previously been observed.
Identifiants
pubmed: 38085665
doi: 10.1097/FBP.0000000000000762
pii: 00008877-990000000-00071
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.
Références
Ahwazi HH, Abdijadid S (2022). Chlordiazepoxide. In StatPearls. Treasure Island (FL): StatPearls Publishing.
Greenwich Biosciences (2021). Epidiolex®: Highlights of prescribing information. Carlsbad, CA: Greenwich Biosciences.
de Almeida DL, Devi LA (2020). Diversity of molecular targets and signaling pathways for CBD. Pharmacol Res Perspect 8:e00682.
Anderson KG, van Haaren F (1999). Cocaine discrimination and time-course effects in male and female Wistar rats. Eur J Pharmacol 382:69–74.
Anderson LL, Absalom NL, Abelev SV, Low IK, Doohan PT, Martin LJ, et al. (2019). Coadministered cannabidiol and clobazam: preclinical evidence for both pharmacodynamic and pharmacokinetic interactions. Epilepsia 60:2224–2234.
Andrews JS, Stephens DN (1990). Drug discrimination models in anxiety and depression. Pharmacol Ther 47:267–280.
Bakas T, van Nieuwenhuijzen PS, Devenish SO, McGregor IS, Arnold JC, Chebib M (2017). The direct actions of cannabidiol and 2-arachidonoyl glycerol at GABAA receptors. Pharmacol Res 119:358–370.
Bates D, Mächler M, Bolker B, Walker S (2015). Fitting linear mixed-effects models using lme4. J Stat Softw 67:1–48.
Bonn-Miller MO, Loflin MJE, Thomas BF, Marcu JP, Hyke T, Vandrey R (2017). Labeling accuracy of cannabidiol extracts sold online. JAMA 318:1708–1709.
Britch SC, Babalonis S, Walsh SL (2021). Cannabidiol: pharmacology and therapeutic targets. Psychopharmacology (Berl) 238:9–28.
Bruner NR, Anderson KG (2009). Discriminative-stimulus and time-course effects of kava-kava (Piper methysticum) in rats. Pharmacol Biochem Behav 92:297–303.
Campo-Soria C, Chang Y, Weiss DS (2006). Mechanism of action of benzodiazepines on GABAA receptors. Br J Pharmacol 148:984–990.
Corroon J, Kight R (2018). Regulatory status of cannabidiol in the United States: a perspective. Cannabis Cannabinoid Res 3:190–194.
Corroon J, Phillips JA (2018). A cross-sectional study of cannabidiol users. Cannabis Cannabinoid Res 3:152–161.
De Gregorio D, McLaughlin RJ, Posa L, Ochoa-Sanchez R, Enns J, Lopez-Canul M, et al. (2019). Cannabidiol modulates serotonergic transmission and reverses both allodynia and anxiety-like behavior in a model of neuropathic pain. Pain 160:136–150.
DeHart WB, Kaplan BA (2019). Applying mixed-effects modeling to single-subject designs: an introduction. J Exp Anal Behav 111:192–206.
Deiana S, Watanabe A, Yamasaki Y, Amada N, Arthur M, Fleming S, et al. (2012). Plasma and brain pharmacokinetic profile of cannabidiol (CBD), cannabidivarine (CBDV), Δ9-tetrahydrocannabivarin (THCV) and cannabigerol (CBG) in rats and mice following oral and intraperitoneal administration and CBD action on obsessive-compulsive behavior. Psychopharmacology (Berl) 219:859–873.
Devinsky O, Cross JH, Laux L, Marsh E, Miller I, Nabbout R, et al.; Cannabidiol in Dravet Syndrome Study Group (2017). Trial of cannabidiol for drug-resistant seizures in the Dravet syndrome. N Engl J Med 376:2011–2020.
Devinsky O, Verducci C, Thiele EA, Laux LC, Patel AD, Filloux F, et al. (2018). Open-label use of highly purified CBD (Epidiolex®) in patients with CDKL5 deficiency disorder and Aicardi, Dup15q, and Doose syndromes. Epilepsy Behav 86:131–137.
Fleshler M, Hoffman HS (1962). A progression for generating variable-interval schedules. J Exp Anal Behav 5:529–530.
Frankot M, Mueller PM, Young ME, Vonder Haar C (2023). Statistical power and false positive rates for interdependent outcomes are strongly influenced by test type: Implications for behavioral neuroscience. Neuropsychopharmacol 48:1612–1622.
Fujiwara A, Shimosawa M, Iino M, Sasaki M, Sato S, Shimoi A (2018). Generalization tests using different dosing routes from those of drug discrimination training in rats. J Toxicol Sci 43:451–458.
García-Gutiérrez MS, Navarrete F, Gasparyan A, Austrich-Olivares A, Sala F, Manzanares J (2020). Cannabidiol: a potential new alternative for the treatment of anxiety, depression, and psychotic disorders. Biomolecules 10:1575.
Gardener H, Wallin C, Bowen J (2022). Heavy metal and phthalate contamination and labeling integrity in a large sample of US commercially available cannabidiol (CBD) products. Sci Total Environ 851:158110.
Gaston TE, Bebin EM, Cutter GR, Ampah SB, Liu Y, Grayson LP, et al.; UAB CBD Program (2019). Drug-drug interactions with cannabidiol (CBD) appear to have no effect on treatment response in an open-label Expanded Access Program. Epilepsy Behav 98:201–206.
Goldenberg MM (2010). Overview of drugs used for epilepsy and seizures: etiology, diagnosis, and treatment. P T 35:392–415.
Gray RA, Heal DJ, Maguire DR, Gerak LR, Javors MA, Smith S, et al. (2022). Preclinical assessment of the abuse potential of purified botanical cannabidiol: self-administration, drug discrimination, and physical dependence. J Pharmacol Exp Ther 382:54–65.
Guimarães FS, Chiaretti TM, Graeff FG, Zuardi AW (1990). Antianxiety effect of cannabidiol in the elevated plus-maze. Psychopharmacology (Berl) 100:558–559.
van Haaren F, Anderson KG, Haworth SC, Kem WR (1999). GTS-21, a mixed nicotinic receptor agonist/antagonist, does not affect the nicotine cue. Pharmacol Biochem Behav 64:439–444.
Hložek T, Uttl L, Kadeřábek L, Balíková M, Lhotková E, Horsley RR, et al. (2017). Pharmacokinetic and behavioural profile of THC, CBD, and THC+CBD combination after pulmonary, oral, and subcutaneous administration in rats and confirmation of conversion in vivo of CBD to THC. Eur Neuropsychopharmacol 27:1223–1237.
Izzo AA, Borrelli F, Capasso R, Di Marzo V, Mechoulam R (2009). Non-psychotropic plant cannabinoids: new therapeutic opportunities from an ancient herb. Trends Pharmacol Sci 30:515–527.
Janisset NR, Romariz SA, Hashiguchi D, Quintella ML, Gimenes C, Yokoyama T, et al. (2022). Partial protective effects of cannabidiol against PTZ-induced acute seizures in female rats during the proestrus–estrus transition. Epilepsy Behav 129:108615.
Johnson E, Kilgore M, Babalonis S (2022). Label accuracy of unregulated cannabidiol (CBD) products: measured concentration vs label claim. J Cannabis Res 4:1–7.
Linares IM, Zuardi AW, Pereira LC, Queiroz RH, Mechoulam R, Guimarães FS, et al. (2019). Cannabidiol presents an inverted U-shaped dose-response curve in a simulated public speaking test. Braz J Psychiatry 41:9–14.
Lingamchetty TN, Hosseini SA, Saadabadi A (2022). Midazolam. In StatPearls. Treasure Island (FL): StatPearls Publishing.
Lucki I, Singh A, Kreiss DS (1994). Antidepressant-like behavioral effects of serotonin receptor agonists. Neurosci Biobehav Rev 18:85–95.
Luke SG (2017). Evaluating significance in linear mixed-effects models in R. Behav Res Methods 49:1494–1502.
Marona-Lewicka D, Nichols DE (1998). Drug discrimination studies of the interoceptive cues produced by selective serotonin uptake inhibitors and selective serotonin releasing agents. Psychopharmacology (Berl) 138:67–75.
McMahon LR (2015). The rise (and fall?) of drug discrimination research. Drug Alcohol Depend 151:284–288.
Mechoulam R, Parker LA, Gallily R (2002). Cannabidiol: an overview of some pharmacological aspects. J Clin Pharmacol 42:11S–19S.
Miller OS, Elder EJ Jr, Jones KJ, Gidal BE (2022). Analysis of cannabidiol (CBD) and THC in nonprescription consumer products: implications for patients and practitioners. Epilepsy Behav 127:108514.
Moltke J, Hindocha C (2021). Reasons for cannabidiol use: a cross-sectional study of CBD users, focusing on self-perceived stress, anxiety, and sleep problems. J Cannabis Res 3:5.
Niu J, Straubinger RM, Mager DE (2019). Pharmacodynamic drug–drug interactions. Clin Pharmacol Ther 105:1395–1406.
Olivier B, Bosch L, van Hest A, van der Heyden J, Mos J, van der Poel G, et al. (1993). Preclinical evidence on the psychotropic profile of fluvoxamine. Pharmacopsychiatry 26:2–9.
Olkkola KT, Ahonen J (2008). Midazolam and other benzodiazepines. Handb Exp Pharmacol 182:335–360.
Onaivi ES, Green MR, Martin BR (1990). Pharmacological characterization of cannabinoids in the elevated plus-maze. Pharmacology 253:1002–1009.
Patel AD, Mazurkiewicz-Bełdzińska M, Chin RF, Gil-Nagel A, Gunning B, Halford JJ, et al. (2021). Long-term safety and efficacy of add-on cannabidiol in patients with Lennox-Gastaut syndrome: Results of a long-term open-label extension trial. Epilepsia 62:2228–2239.
Resstel LB, Joca SR, Moreira FA, Corrêa FM, Guimarães FS (2006). Effects of cannabidiol and diazepam on behavioral and cardiovascular responses induced by contextual conditioned fear in rats. Behav Brain Res 172:294–298.
Ruffolo G, Cifelli P, Roseti C, Thom M, van Vliet EA, Limatola C, et al. (2018). A novel GABAergic dysfunction in human Dravet syndrome. Epilepsia 59:2106–2117.
Sigel E, Ernst M (2018). The benzodiazepine binding sites of GABAA receptors. Trends Pharmacol Sci 39:659–671.
Stolerman I (1993). Drug discrimination. In: Methods in behavioral pharmacology. van Haaren F (editor). Amsterdam: Elsevier; pp. 217–243.
Thiele EA, Marsh ED, French JA, Mazurkiewicz-Beldzinska M, Benbadis SR, Joshi C, et al.; GWPCARE4 Study Group (2018). Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 391:1085–1096.
Uttl L, Hložek T, Mareš P, Páleníček T, Kubová H (2021). Anticonvulsive effects and pharmacokinetic profile of cannabidiol (CBD) in the pentylenetetrazol (PTZ) or N-methyl-D-aspartate (NMDA) models of seizures in infantile rats. Int J Mol Sci 23:94.
Wiley JL, Taylor SI, Marusich JA (2021). Δ9-Tetrahydrocannabinol discrimination: effects of route of administration in rats. Drug Alcohol Depend 225:108827.
Woudenberg F, Slangen JL (1989). Discriminative stimulus properties of midazolam: comparison with other benzodiazepines. Psychopharmacology (Berl) 97:466–470.
Young R (2009). Drug discrimination. In: Methods of behavior analysis in neuroscience. Buccafusco JJ (editor). Boca Raton (FL): CRC Press/Taylor & Francis.
Young ME (2018). Discounting: a practical guide to multilevel analysis of choice data. J Exp Anal Behav 109:293–312.